Related Experiment Video

Updated: May 10, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Crizotinib in the treatment of non-small-cell lung carcinoma

Adam Płużański1, Aleksandra Piórek, Maciej Krzakowski

  • 1Lung Cancer Department, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland.

Contemporary Oncology (Poznan, Poland)
|June 22, 2013
PubMed

Insights

Crizotinib effectively treats advanced non-small-cell lung cancer (NSCLC) in patients with anaplastic lymphoma kinase (ALK) gene rearrangement, showing significant response rates and progression-free survival. This review covers its efficacy, safety, and resistance mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal Growth Factor Receptor (EGFR) inhibitors benefit advanced non-small-cell lung cancer (NSCLC).
  • Anaplastic Lymphoma Kinase (ALK) pathway activation and EML4-ALK fusion gene are emerging molecular targets in NSCLC pathogenesis and treatment.
  • ALK gene rearrangement occurs in 3-5% of NSCLC patients.

Purpose of the Study:

  • To provide an overview of crizotinib's role in treating NSCLC patients with ALK gene defects.
  • To discuss molecular diagnosis, clinical trial results, and safety profiles of crizotinib.
  • To address drug resistance causes and management strategies for treatment failure.

Main Methods:

  • Literature review of studies on crizotinib in ALK-rearranged NSCLC.
  • Analysis of clinical trial data assessing crizotinib efficacy and safety.
  • Examination of molecular diagnostic methods for ALK aberrations.

Main Results:

  • Crizotinib, an ALK inhibitor, demonstrates a 7-10 month progression-free survival and 50-60% objective response rate in ALK-rearranged NSCLC.
  • Clinical trials confirm crizotinib's efficacy and safety profile in this patient subset.
  • Understanding resistance mechanisms is crucial for long-term treatment success.

Conclusions:

  • Crizotinib is an effective targeted therapy for NSCLC patients with ALK gene rearrangement.
  • Molecular diagnosis of ALK status is essential for patient selection.
  • Further research into overcoming drug resistance is necessary for improved patient outcomes.
Keywords:
ALKcrizotinibfusion genenon-small-cell lung cancertyrosine kinase inhibitor

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...